EA202192045A1 - Средства для диагностической визуализации ракового заболевания - Google Patents
Средства для диагностической визуализации ракового заболеванияInfo
- Publication number
- EA202192045A1 EA202192045A1 EA202192045A EA202192045A EA202192045A1 EA 202192045 A1 EA202192045 A1 EA 202192045A1 EA 202192045 A EA202192045 A EA 202192045A EA 202192045 A EA202192045 A EA 202192045A EA 202192045 A1 EA202192045 A1 EA 202192045A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- sifa
- diagnostic visualization
- silicon
- atom
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000012800 visualization Methods 0.000 title 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 229910052710 silicon Inorganic materials 0.000 abstract 1
- 239000010703 silicon Substances 0.000 abstract 1
- ABTOQLMXBSRXSM-UHFFFAOYSA-N silicon tetrafluoride Chemical compound F[Si](F)(F)F ABTOQLMXBSRXSM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/12—Organo silicon halides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nuclear Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к конъюгату лиганд-SIFA-хелатор, содержащему в одной молекуле три отдельные группы: (a) один или несколько лигандов, которые способны связываться с PSMA, (b) фрагмент акцептора кремния-фторида (SIFA), который включает ковалентную связь между атомом кремния и атомом фтора, и (c) одну или несколько хелатных групп, содержащих хелатный нерадиоактивный катион.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19154495 | 2019-01-30 | ||
| PCT/EP2020/052268 WO2020157184A1 (en) | 2019-01-30 | 2020-01-30 | Cancer diagnostic imaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192045A1 true EA202192045A1 (ru) | 2021-10-27 |
Family
ID=65268807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192045A EA202192045A1 (ru) | 2019-01-30 | 2020-01-30 | Средства для диагностической визуализации ракового заболевания |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220118120A1 (ru) |
| EP (1) | EP3917582A1 (ru) |
| JP (1) | JP2022518956A (ru) |
| KR (1) | KR20210153036A (ru) |
| CN (2) | CN113573743B (ru) |
| AU (2) | AU2020215086A1 (ru) |
| BR (1) | BR112021015035A2 (ru) |
| CA (1) | CA3128406A1 (ru) |
| EA (1) | EA202192045A1 (ru) |
| IL (2) | IL303420A (ru) |
| MX (2) | MX2021008809A (ru) |
| SG (1) | SG11202107822PA (ru) |
| WO (1) | WO2020157184A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4185336A1 (en) * | 2020-07-23 | 2023-05-31 | Technische Universität München | Silicon-containing ligand compounds |
| EP4023250A1 (en) | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| EP4291250A1 (en) | 2021-02-15 | 2023-12-20 | Technische Universität München | Dual mode radiotracer and therapeutics |
| GB202108779D0 (en) | 2021-06-18 | 2021-08-04 | Blue Earth Diagnostics Ltd | Si-at therapeutic/diagnostic compounds |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| GB202113646D0 (en) | 2021-09-24 | 2021-11-10 | Blue Earth Diagnostics Ltd | Method of preparation of 18F labelled silyl-fluoride compounds |
| WO2023205755A2 (en) * | 2022-04-20 | 2023-10-26 | Fuzionaire Diagnostics, Inc. | Theranostic silicon-fluoride heteroaromatic systems and methods thereof |
| GB202207372D0 (en) | 2022-05-19 | 2022-07-06 | Blue Earth Diagnostics Ltd | Synthesis of fluorosilyl compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114381B2 (en) * | 2004-02-13 | 2012-02-14 | The University Of British Columbia | Radiolabeled compounds and compositions, their precursors and methods for their production |
| WO2016062370A1 (en) * | 2014-10-20 | 2016-04-28 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CN111132700B (zh) * | 2017-07-28 | 2022-12-13 | 慕尼黑工业大学 | 双模放射性示踪剂与治疗剂 |
-
2020
- 2020-01-30 CN CN202080021643.8A patent/CN113573743B/zh active Active
- 2020-01-30 SG SG11202107822PA patent/SG11202107822PA/en unknown
- 2020-01-30 JP JP2021544523A patent/JP2022518956A/ja active Pending
- 2020-01-30 AU AU2020215086A patent/AU2020215086A1/en active Pending
- 2020-01-30 KR KR1020217027156A patent/KR20210153036A/ko unknown
- 2020-01-30 IL IL303420A patent/IL303420A/en unknown
- 2020-01-30 CN CN202310612449.2A patent/CN116585494A/zh active Pending
- 2020-01-30 BR BR112021015035-8A patent/BR112021015035A2/pt unknown
- 2020-01-30 EA EA202192045A patent/EA202192045A1/ru unknown
- 2020-01-30 MX MX2021008809A patent/MX2021008809A/es unknown
- 2020-01-30 US US17/427,006 patent/US20220118120A1/en active Pending
- 2020-01-30 CA CA3128406A patent/CA3128406A1/en active Pending
- 2020-01-30 WO PCT/EP2020/052268 patent/WO2020157184A1/en unknown
- 2020-01-30 EP EP20702638.6A patent/EP3917582A1/en active Pending
-
2021
- 2021-07-19 IL IL284963A patent/IL284963A/en unknown
- 2021-07-22 MX MX2023006274A patent/MX2023006274A/es unknown
-
2023
- 2023-07-24 AU AU2023208070A patent/AU2023208070A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023006274A (es) | 2023-06-13 |
| JP2022518956A (ja) | 2022-03-17 |
| SG11202107822PA (en) | 2021-08-30 |
| CA3128406A1 (en) | 2020-08-06 |
| WO2020157184A1 (en) | 2020-08-06 |
| EP3917582A1 (en) | 2021-12-08 |
| CN116585494A (zh) | 2023-08-15 |
| IL303420A (en) | 2023-08-01 |
| AU2020215086A1 (en) | 2021-08-05 |
| MX2021008809A (es) | 2021-11-12 |
| KR20210153036A (ko) | 2021-12-16 |
| US20220118120A1 (en) | 2022-04-21 |
| CN113573743A (zh) | 2021-10-29 |
| AU2023208070A1 (en) | 2023-08-10 |
| CN113573743B (zh) | 2023-11-07 |
| BR112021015035A2 (pt) | 2021-10-05 |
| IL284963A (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202192045A1 (ru) | Средства для диагностической визуализации ракового заболевания | |
| EA202090370A1 (ru) | Двухрежимная радиоактивная метка и радиотерапевтическое средство | |
| EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
| MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
| NI202000086A (es) | Agentes vinculantes de psma y usos de los mismos | |
| PH12020550898A1 (en) | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide | |
| PH12018500062A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| MD3443009T2 (ro) | Anticorpi anti-TIM-3 și compoziții | |
| EA201690862A1 (ru) | Соединения для позитронно-эмиссионной томографии | |
| EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
| MY197836A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
| MD3313884T2 (ro) | Anticorpi anti-CD123 şi conjugaţi şi derivaţi ai acestora | |
| WO2015184349A3 (en) | Multivalent ras binding compounds | |
| MD3468965T2 (ro) | Compuși de 1-tetrahidropiranilcarbonil-2,3-dihidro-1 H-indol pentru tratamentul cancerului | |
| EA201992595A1 (ru) | Усиление фармакокинетики бифункциональных хелатов и их применения | |
| MX2021000397A (es) | Moleculas de union a mesotelina y cd137. | |
| EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
| BR112022021884A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e clec12a | |
| EA202090116A1 (ru) | Композиции, содержащие конъюгаты каннабиноидного аналога, и способы применения | |
| EA201890898A1 (ru) | Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение | |
| PH12019500802A1 (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
| MX2018000239A (es) | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. | |
| MA50280A (fr) | Procédés et compositions pour améliorer l'immunogénicité de tumeurs [ | |
| MX2021015976A (es) | Fusiones de inmunoglobulina y transtiretina multiespecificas. |